Logo

ACXP

Acurx Pharmaceuticals, Inc.

ACXP

Acurx Pharmaceuticals, Inc. • NASDAQ
$3.86 ▲ 2.93% (+0.11)
Market Cap $6.12 M
52w High $25.80
52w Low $3.75
Dividend Yield 0%
P/E -0.47
Volume 11.13K
Outstanding Shares 1.58M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.029M ▼ $-1.993M ▲ 0% $-1.23 ▲ $-1.993M ▲
Q2-2025 $0 $2.27M ▲ $-2.246M ▼ 0% $-1.89 ▲ $-2.27M ▼
Q1-2025 $0 $2.149M ▼ $-2.149M ▲ 0% $-2.14 ▲ $0
Q4-2024 $0 $2.782M ▼ $-2.782M ▲ 0% $-3.27 ▲ $0
Q3-2024 $0 $2.822M $-2.822M 0% $-3.45 $0

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.907B ▲ $6.105B ▲ $2.468B ▲ $3.637B ▲
Q2-2025 $6.064M ▲ $6.158M ▲ $2.592M ▲ $3.566M ▲
Q1-2025 $4.644M ▲ $4.805M ▲ $2.494M ▼ $2.311M ▲
Q4-2024 $3.707M ▼ $3.858M ▼ $3.243M ▼ $615.121K ▼
Q3-2024 $5.763M $5.983M $3.319M $2.664M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.993M ▲ $-1.881M ▼ $0 $1.724M ▼ $-157.326K ▼ $-1.881M ▼
Q2-2025 $-2.246M ▼ $-1.671M ▲ $0 $3.091M ▲ $1.42M ▲ $-1.671M ▲
Q1-2025 $-2.149M ▲ $-2.051M ▲ $0 $2.989M ▲ $937.174K ▲ $-2.051M ▲
Q4-2024 $-2.782M ▲ $-2.25M ▼ $0 $194.547K ▼ $-2.056M ▼ $-2.25M ▼
Q3-2024 $-2.822M $-2.19M $0 $1.592M $-598.294K $-2.19M

Five-Year Company Overview

Income Statement

Income Statement Acurx is a classic early‑stage biotech story: there is essentially no product revenue yet, and the company runs at a steady loss driven by research, clinical development, and overhead. Losses have been fairly consistent over the past several years, which suggests controlled spending rather than sudden spikes, but also highlights that the business is still entirely dependent on outside funding rather than internal cash generation. Earnings per share look very negative mainly because costs are being spread over a relatively small base, not because of large commercial operations. Overall, the income statement reflects a pre‑commercial R&D platform rather than an operating business.

Balance Sheet

Balance Sheet The balance sheet is very lean. Assets are small and largely made up of cash, with no meaningful physical assets or inventory, which is typical for a clinical‑stage biotech. There is no reported financial debt, which is a plus from a risk standpoint, but equity levels are also modest, underlining the company’s limited size and capital base. In practical terms, this means Acurx has a simple, clean capital structure but will likely need periodic capital raises to support trials and future growth unless it secures partnerships or non‑dilutive funding.

Cash Flow

Cash Flow Cash flow patterns match the income statement: money is flowing out to fund operations and clinical work, with no offsetting inflow from product sales. Operating cash burn appears relatively steady from year to year, suggesting some discipline in spending plans. There is little to no capital expenditure, so free cash flow is essentially the same as operating cash flow, and both are negative. The main cash‑flow risk is duration: the longer late‑stage trials and regulatory processes take, the more the company will rely on fresh capital to maintain its programs.

Competitive Edge

Competitive Edge Acurx is aiming at a focused niche within infectious disease: serious Gram‑positive bacterial infections, starting with C. difficile. Its lead candidate targets a novel enzyme that competitors have not yet exploited, which could offer an edge in effectiveness against resistant strains. Microbiome‑sparing activity and FDA designations like Fast Track and QIDP add to its differentiation. However, the company is small, with only one main clinical asset and another in preclinical development, while competing against established antibiotics, emerging microbiome therapies, and much larger pharma players. Its moat depends heavily on patents, regulatory exclusivities, and being first to successfully bring this new mechanism to market.

Innovation and R&D

Innovation and R&D Innovation is the heart of Acurx’s story. The company is developing a first‑in‑class antibiotic mechanism that has already shown promising mid‑stage clinical results in C. difficile, with strong cure rates and a potentially better profile for preserving the gut microbiome. Beyond the lead drug, Acurx is building a broader platform around the same target to address other resistant infections such as MRSA and VRE, including both oral and intravenous forms. It also uses AI‑supported discovery tools in collaboration with external partners to expand and refine its pipeline. The R&D strategy is focused, science‑driven, and leverages regulatory incentives, but it concentrates risk in one main biological target and in the successful execution of pivotal trials.

Summary

Acurx is an early‑stage, pre‑revenue biotech focused on developing a new class of antibiotics against high‑priority, drug‑resistant infections. Financially, it has a simple, mostly cash‑based balance sheet with no debt, persistent operating losses, and ongoing cash burn typical of a company in its stage of development. The investment case hinges almost entirely on scientific and clinical outcomes rather than current financial performance. If its lead candidate and follow‑on compounds continue to perform well in late‑stage trials and secure approval, the company’s profile could change substantially. Until then, the main themes are scientific promise, regulatory tailwinds, high clinical and funding risk, and significant uncertainty on timing and scale of any eventual commercial success.

NEWS

November 18, 2025 · 8:00 AM UTC

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Read more

November 12, 2025 · 7:01 AM UTC

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

Read more

November 10, 2025 · 8:00 AM UTC

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

Read more

October 28, 2025 · 8:00 AM UTC

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

Read more

October 27, 2025 · 8:00 AM UTC

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

Read more